Screener
Protagonist Therapeutics PTGX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Protagonist Therapeutics’s reported figures.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
FAQ
- What is Protagonist Therapeutics's enterprise value?
- Protagonist Therapeutics (PTGX) reported enterprise value of $7.47B in Q2 2026.
- How has Protagonist Therapeutics's enterprise value changed year-over-year?
- Protagonist Therapeutics's enterprise value increased by 135.7% year-over-year, from $3.17B to $7.47B.
- What is the long-term trend for Protagonist Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's enterprise value has grown at a 44.4% compound annual growth rate (CAGR), from $850.8M to $5.34B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Protagonist Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude